CBR Pharma Successfully Raises Seed Funding for State-of-the-Art Facility in Shannon

_{For Release - Monday 3rd June 2023}

CBR Pharma, a dynamic Contract and Development Manufacturing Company, is delighted to announce the successful completion of its seed fund raise.

With a strong commitment to innovation and quality, CBR Pharma is poised to establish a state-of-the-art facility in Shannon, Ireland, dedicated to the production of Active Pharmaceutical Ingredient (API) Cannabinoids for pharmaceutical companies engaged in the manufacturing of FDA/EMA approved medicines.
‍

"We are thrilled to have raised €300,000 in our seed funding round, marking a significant milestone for CBR Pharma" Cormac MacGowan, Founder of CBR Pharma Ltd.

^{Cormac MacGowan - Founder of CBR Pharma}

CBR Pharma has successfully raised €300,000 in its first funding round, which will serve as a crucial stepping stone towards raising the main fund required to establish the production facility and obtain Good Manufacturing Practice (GMP) certification for its API Cannabinoids. With a strategic plan in place, CBR Pharma anticipates shipping certified products to pharmaceutical partners within 24 months of securing the necessary funds.
‍

CBR Pharma is confident that the EU will emerge as a global center for the production of GMP API cannabinoids, and the company is determined to play a leading role in this sector.
‍
By establishing its facility in Shannon, CBR Pharma aims to position Ireland at the forefront of cannabinoid API production in the EU and contribute to the growth and development of the industry.
‍

CBR Pharma is currently in discussions with various fundraising partners, including a prominent Californian investment bank, for the completion of its next round of funding. An exciting announcement regarding this partnership is expected to be made soon, further advancing CBR Pharma's mission.
‍
This funding will propel us closer to our goal of establishing a cutting-edge manufacturing facility in Shannon. Our vision is to position Ireland as the EU capital of cannabinoid APIs, serving as a hub for the production of high-quality API Cannabinoids that will support the development and supply of FDA/EMA approved medicines.
‍

Cormac MacGowan - Founder of CBR Pharma Ltd
Email: cormacmacgowan@cbrpharma.com Phone: +353 (87) 677 7251


‍
‍

• Industry Expertise: With a team of experienced professionals, we possess in-depth knowledge of cannabinoid manufacturing and pharmaceutical development. Our expertise in navigating the complexities of GMP for API standards enables us to deliver high-quality cannabinoids that meet the stringent requirements of our pharmaceutical partners.
• Investor Opportunities: CBR Pharma welcomes interested investors who share our vision of becoming a global leading supplier of GMP API Cannabinoids. While we strive to create investment opportunities and collaborations, please note that the information provided represents our current plans and is subject to change.
• Pharmaceutical Partnerships: We invite pharmaceutical companies interested in sourcing high-quality cannabinoid products for their FDA/EMA approved medicines to consider partnering with CBR Pharma. Our commitment to meeting the GMP for API standards ensures that our cannabinoids meet the rigorous requirements for active pharmaceutical ingredients.

Choose CBR Pharma for our dedication to GMP API Cannabinoids, our commitment to meeting the GMP
for API standards in our future state-of-the-art facility, regulatory compliance, industry expertise, investor
opportunities, and pharmaceutical partnerships.

_{[1] Disclaimer: This information is presented as part of our plans and should not be construed as a guarantee. The content provided is subject to change, and it does not constitute an offer or solicitation to sell securities or an invitation to offer to buy or subscribe for any securities. The information contained herein is confidential and should be treated as such. Any projections or forward-looking statements are based on certain assumptions and may not reflect actual results. The Company does not undertake any obligation to update the information herein to reflect actual results or changes in assumptions or other factors. The accuracy of economic and market information obtained from published sources or prepared by other parties is not guaranteed. The Company has no operating history, and past performance by the principals is not indicative of future performance by the Company.}